Failure of glucagon to stimulate ketone body production during acute insulin deficiency or insulin replacement in man.

Sonnenberg GE, Stauffacher W, Keller U

Diabetologia1 Aug 1982Cited by 19 (Europe PMC)

PMID6127275DOI10.1007/bf01271167PepBankPUB-06127275

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialActivity measurement
In normal subjects during insulin deficiency, glucagon replacement failed to enhance ketogenesis.
In plain wordsIn normal subjects during insulin deficiency, glucagon replacement did not increase ketone production compared with no glucagon replacement.
Peptide
Glucagon
Outcome
No significant changeKetogenesis during insulin deficiency
Study
n: not reported in source
Comparator
Insulin deficiency without glucagon replacement
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
2 ng . kg-1 . min-1 · infusionAs given in this study (human).
Source sentences
Summary
Glucagon replacement (2 ng . kg-1 . min-1) during insulin deficiency failed to enhance ketogenesis or lipolysis but lowered the beta-hydroxybutyrate/acetoacetate concentration ratios.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the role of glucagon and insulin in the acute regulation of ketone body kinetics in man, somatostatin was administered with various combinations of these hormones by replacement infusions in groups of six to seven normal subjects.
Report a problemFND-0612727501
02HumanNon-randomized trialActivity measurement
In normal subjects during insulin deficiency, glucagon replacement failed to enhance lipolysis.
In plain wordsIn normal subjects during insulin deficiency, glucagon replacement did not increase fat breakdown compared with no glucagon replacement.
Peptide
Glucagon
Outcome
No significant changeLipolysis during insulin deficiency
Study
n: not reported in source
Comparator
Insulin deficiency without glucagon replacement
Outcome group
Lipids · Metabolic and weight
Studied dose
2 ng . kg-1 . min-1 · infusionAs given in this study (human).
Source sentences
Summary
Glucagon replacement (2 ng . kg-1 . min-1) during insulin deficiency failed to enhance ketogenesis or lipolysis but lowered the beta-hydroxybutyrate/acetoacetate concentration ratios.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the role of glucagon and insulin in the acute regulation of ketone body kinetics in man, somatostatin was administered with various combinations of these hormones by replacement infusions in groups of six to seven normal subjects.
Report a problemFND-0612727502
03HumanNon-randomized trialActivity measurement
In normal subjects during insulin deficiency, glucagon replacement lowered the beta-hydroxybutyrate/acetoacetate concentration ratio.
In plain wordsIn normal subjects during insulin deficiency, glucagon replacement lowered the ratio of two ketone bodies compared with no glucagon replacement.
Peptide
Glucagon
Outcome
DecreaseBeta-hydroxybutyrate/acetoacetate ratio
Study
n: not reported in source
Comparator
Insulin deficiency without glucagon replacement
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
2 ng . kg-1 . min-1 · infusionAs given in this study (human).
Source sentences
Summary
Glucagon replacement (2 ng . kg-1 . min-1) during insulin deficiency failed to enhance ketogenesis or lipolysis but lowered the beta-hydroxybutyrate/acetoacetate concentration ratios.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the role of glucagon and insulin in the acute regulation of ketone body kinetics in man, somatostatin was administered with various combinations of these hormones by replacement infusions in groups of six to seven normal subjects.
Report a problemFND-0612727503
04HumanNon-randomized trialActivity measurement
In normal subjects, hyperglycaemia occurred during glucagon administration and insulin deficiency.
In plain wordsIn normal subjects, high blood sugar occurred during glucagon administration and insulin deficiency.
Peptide
Glucagon
Outcome
IncreaseHyperglycaemia during insulin deficiency
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 ng . kg-1 . min-1 · infusionAs given in this study (human).
Source sentences
Summary
Hyperglycaemia, observed during glucagon administration and insulin deficiency
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the role of glucagon and insulin in the acute regulation of ketone body kinetics in man, somatostatin was administered with various combinations of these hormones by replacement infusions in groups of six to seven normal subjects.
Report a problemFND-0612727504
05HumanNon-randomized trialActivity measurement
In normal subjects receiving somatostatin and insulin replacement, glucagon infusions did not accelerate ketone body production.
In plain wordsIn normal subjects receiving somatostatin and insulin replacement, glucagon did not increase ketone production compared with no added glucagon.
Peptide
Glucagon
Outcome
No significant changeKetone body production with insulin replacement
Study
n: not reported in source
Comparator
Somatostatin and insulin replacement without added glucagon
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
2 and 4 ng . kg-1 . min-1 · infusionAs given in this study (human).
Source sentences
Summary
Glucagon infusions (2 and 4 ng . kg-1 . min-1) during somatostatin and insulin replacement did not accelerate ketone body production or raise non-esterified fatty acid levels, but produced a dose-dependent elevation of blood glucose levels.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the role of glucagon and insulin in the acute regulation of ketone body kinetics in man, somatostatin was administered with various combinations of these hormones by replacement infusions in groups of six to seven normal subjects.
Report a problemFND-0612727505
06HumanNon-randomized trialActivity measurement
In normal subjects receiving somatostatin and insulin replacement, glucagon infusions did not raise non-esterified fatty acid levels.
In plain wordsIn normal subjects receiving somatostatin and insulin replacement, glucagon did not raise free fatty acids compared with no added glucagon.
Peptide
Glucagon
Outcome
No significant changeNon-esterified fatty acids with insulin replacement
Study
n: not reported in source
Comparator
Somatostatin and insulin replacement without added glucagon
Outcome group
Lipids · Metabolic and weight
Studied dose
2 and 4 ng . kg-1 . min-1 · infusionAs given in this study (human).
Source sentences
Summary
Glucagon infusions (2 and 4 ng . kg-1 . min-1) during somatostatin and insulin replacement did not accelerate ketone body production or raise non-esterified fatty acid levels, but produced a dose-dependent elevation of blood glucose levels.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the role of glucagon and insulin in the acute regulation of ketone body kinetics in man, somatostatin was administered with various combinations of these hormones by replacement infusions in groups of six to seven normal subjects.
Report a problemFND-0612727506
07HumanNon-randomized trialActivity measurement
In normal subjects receiving somatostatin and insulin replacement, glucagon produced a dose-dependent elevation of blood glucose.
In plain wordsIn normal subjects receiving somatostatin and insulin replacement, glucagon raised blood sugar with increasing dose compared with no added glucagon.
Peptide
Glucagon
Outcome
IncreaseDose-dependent blood glucose elevation
Study
n: not reported in source
Comparator
Somatostatin and insulin replacement without added glucagon
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 and 4 ng . kg-1 . min-1 · infusionAs given in this study (human).
Source sentences
Summary
Glucagon infusions (2 and 4 ng . kg-1 . min-1) during somatostatin and insulin replacement did not accelerate ketone body production or raise non-esterified fatty acid levels, but produced a dose-dependent elevation of blood glucose levels.
1 context sentence(design, population, supporting numbers)
Summary · context
To assess the role of glucagon and insulin in the acute regulation of ketone body kinetics in man, somatostatin was administered with various combinations of these hormones by replacement infusions in groups of six to seven normal subjects.
Report a problemFND-0612727507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.